BIAL attended this Congress with a booth and the presentation of 4 posters on Opicapone, the second medicine of BIAL's own Research & Development for Parkinson’s Disease, which was approved by the European Commission in 2016.
This is one of the most relevant events within the area, and it is organized by the International Parkinson and Movement Disorder Society.
More than 4.000 people from 89 counties and 40 companies attended this 21st edition.
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.
